Study on Personalized Medicine to Improve Drug Treatment for Cancer Patients Taking Antidepressants, Painkillers, or Antiemetics

What this Trial Is About

Researchers are evaluating how personalized medicine clinic recommendations affect drug levels, effectiveness, and side effects of commonly used antidepressants, pain medications, and antiemetics in adult cancer patients. The study focuses on the impact of genetic differences and drug interactions on treatment with these medications. It aims to see if these personalized recommendations improve drug response and reduce side effects over six months. The study involves three groups of cancer patients taking specific medications antidepressants citalopram, escitalopram, venlafaxine, desvenlafaxine, opioid pain medications codeine, oxycodone, hydrocodone, tramadol, and the antiemetic ondansetron. Patients will attend a personalized medicine clinic for genotype-guided treatment advice considering drug interactions. They will have visits at screening, then 0.5, 4 virtual, and 7 months after, with blood samples and clinical data collected. Participants will complete surveys measuring symptoms like depression, pain, nausea, and medication side effects at each visit. Drug levels and treatment effectiveness will be assessed at baseline and six months after recommendations. This will help researchers understand how genetics and drug interactions affect medication response in cancer care. The total study participation lasts about seven months with ongoing monitoring of symptoms and drug exposure.

Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer